ArticleESMO open2024

The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study.

L Yi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.